Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

yttrium Y 90 monoclonal antibody Lym-1

Known as: yttrium Y 90 MOAB Lym-1, monoclonal antibody Lym-1, yttrium Y 90, MOAB Lym-1, yttrium Y 90 
A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with yttrium 90 (Y-90). MoAb Lym-1 recognizes an epitope of the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Background: About one-third of patients with relapsed B-cell malignancies develop human anti-mouse antibody (HAMA) following… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?
2000
2000
Radioimmunotherapy using radiolabeled monoclonal antibodies against tumor-associated antigens has been efficacious, particularly… Expand
Is this relevant?
1999
1999
Antilymphoma mouse monoclonal antibody (MoAb) Lym-1, labeled with 67Cu or 131I, has demonstrated promising results in… Expand
Is this relevant?
1999
1999
Copper-67 (67Cu) has ideal properties for radioimmunotherapy. The 62-h half-life is similar to the residence time of antibodies… Expand
Is this relevant?
1998
1998
PURPOSE This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non… Expand
Is this relevant?
1998
1998
PURPOSE Lym-1, a monoclonal antibody (MoAb) that preferentially targets malignant lymphocytes, has induced therapeutic responses… Expand
Is this relevant?
1997
1997
BACKGROUND Because most patients with advanced non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to… Expand
Is this relevant?
1996
1996
A murine antihuman B-cell monoclonal antibody, Lym-1, has shown considerable promise for the treatment of human malignant… Expand
Is this relevant?
1994
1994
BACKGROUND Although chronic lymphocytic leukemia is usually indolent and responsive to treatment early in its course, later… Expand
Is this relevant?
1990
1990
Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?